A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-07-28Est. Completion: 2022-09-23
Enrollment target: 55 participants
Locations
Prometheus Biosciences Selected Site, Los Angeles, California, United States
Prometheus Biosciences Selected Site, Los Angeles, California, United States
Prometheus Biosciences Selected Site, Liberty, Kansas, United States
Prometheus Biosciences Selected Site, Chesterfield, Michigan, United States
Prometheus Biosciences Selected Site, Ypsilanti, Michigan, United States
Prometheus Biosciences Selected Site, St Louis, Missouri, United States
Prometheus Biosciences Selected Site, Lebanon, New Hampshire, United States
Prometheus Biosciences Selected Site, New York, New York, United States
Prometheus Biosciences Selected Site, Garland, Texas, United States
Prometheus Biosciences Selected Site, Lubbock, Texas, United States
Prometheus Biosciences Selected Site, Lubbock, Texas, United States
Prometheus Biosciences Selected Site, San Antonio, Texas, United States
Prometheus Biosciences Selected Site, Southlake, Texas, United States
Prometheus Biosciences Selected Site, Tyler, Texas, United States
Prometheus Biosciences Selected Site, Bellevue, Washington, United States
Other microbiome trials you might be interested in
MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006) | MicrobiomeTrials
Prometheus Biosciences Selected Site, Tacoma, Washington, United States
Prometheus Biosciences Selected Site, Bankstown, New South Wales, Australia
Prometheus Biosciences Selected Site, Woolloongabba, Queensland, Australia
Prometheus Biosciences Selected Site, Adelaide, South Australia, Australia